Today
+0.62%
5 Days
+3.62%
1 Month
-4.71%
6 Months
+21.80%
Year to Date
+13.14%
1 Year
+34.91%
• Elevance Health shares declined due to rising medical loss ratios and healthcare utilization rates. • Higher specialty pharmacy and orthopedic surgery costs forced reassessment of full-year margin targets. • Stringent CMS reimbursement policies and regulatory pressures negatively impact long-term margin outlooks.
• Intuitive Surgical shares rose on optimism regarding upcoming second-quarter earnings and procedure volume growth. • Expanding adoption of the Ion endoluminal system drives growth and strengthens market differentiation. • Stabilizing interest rates improve hospital capital expenditure, supporting future robotic platform sales.
• FDA alert on surgical stapler reloads contributes to stock decline. • Analyst price target trims and valuation debates add to cautious sentiment. • Increased competition and insider selling also pressure the stock.
• Elevance Health reaffirmed 2026 guidance, but stock price declined. • Market headwinds and valuation concerns contributed to stock's movement. • Past regulatory issues and investor caution may persist.
• Elevance Health projects lower 2026 earnings and revenue. • Risk-based membership decline, especially Medicare Advantage, is expected. • Industry faces rising costs, shrinking reimbursements, and regulatory uncertainty.
• Institutional investors increased Elevance Health stake significantly. • Elevance Health raised its quarterly dividend to $1.72 per share. • Q4 2025 earnings per share surpassed analyst estimates.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.61% |
| BlackRock Institutional Trust Company, N.A. | 5.41% |
| State Street Investment Management (US) | 4.76% |
| Wellington Management Company, LLP | 3.82% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 50.16% |
| Investment Advisor/Hedge Fund | 33.29% |
| Hedge Fund | 2.81% |
| Pension Fund | 2.50% |
Related Instruments
Popular Instruments